American Journal of Psychiatry · 1999 · 239 citations · 16 references
PharmacyPharmacotherapyPsychiatryPsychiatric AssessmentPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyBipolar DisordersMood Stabilizer TherapyTreatment Of Mental DisordersTreatment-resistant Psychiatric DisordersAdd-on TherapyAntipsychotic ActionAntipsychotic Medication UseAtypical Antipsychotic TreatmentBipolar I Disorder PharmacotherapyNegative Mood SymptomsNegative Symptoms AssessmentPsychiatric Rating Scales
OBJECTIVE: Case series and follow-up studies suggest that clozapine may have mood-stabilizing properties in addition to antipsychotic action in patients with schizoaffective disorder, bipolar type, and bipolar I disorder, but the generalizability of these findings is limited. This article describes a randomized, open study of clozapine add-on therapy versus treatment as usual for patients with treatment-resistant illness and a history of mania. METHOD: Thirty-eight patients meeting the DSM-IV criteria for schizoaffective or bipolar disorder that was deemed treatment-resistant were randomly assigned to clozapine add-on treatment (N = 19) or treatment as usual (no clozapine) (N = 19) and followed up for 1 year. Patients received monthly ratings on the Brief Psychiatric Rating Scale, Clinical Global Impression scale, Bech-Rafaelsen Mania Scale, Hamilton Depression Rating Scale, Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Abnormal Involuntary Movement Scale, and a 40-item side effect checklist. Differences between treatment groups were assessed according to a pattern-mix random-regression model. An additional analysis compared group differences in rating scale scores against relative time in the study. RESULTS: Significant between-group differences were found in scores on all rating scales except the Hamilton depression scale. Total medication use over 1 year significantly decreased in the clozapine group. No significant differences between groups in somatic complaints were noted. The subjects with nonpsychotic bipolar I disorder who received clozapine showed a degree of improvement similar to that of the entire clozapine-treated group. Clozapine dose was significantly higher for the patients with schizoaffective illness than for those with bipolar disorder. CONCLUSIONS: The results of this study support clozapine's independent mood-stabilizing property. They demonstrate that clozapine use was associated with significant clinical improvement relative to treatment as usual.
16
The Structured Clinical Interview for DSM-III-R (SCID)
Robert L. Spitzer · Archives of General Psychiatry · 1992 · 4.4K citations
Education, Psychiatry, Psychology +14
Clozapine for the Treatment-Resistant Schizophrenic
John M. Kane · Archives of General Psychiatry · 1988 · 4.1K citations
Medicine, Pharmacology, Psychiatry +16
Charles Krauthammer · Archives of General Psychiatry · 1978 · 654 citations
Medicine, Neurology, Psychiatry +8